Aprea Therapeutics, Inc., headquarted at 3805 Old Easton Road in Doylestown, has reported their financial results for the second fiscal quarter of 2023. Staff writers at GlobeNewsWire discussed the updates.

As of June 30, Aprea reported cash and cash equivalents of $27.7 million. For the second quarter of the year, the company reported an operating loss of $3.7 million, compared to an operating loss of $98.5 million for the same period in 2022.

“We continue to execute across all our programs, with notable progress in enrollment in our lead Phase 1/2a dose escalation study with ATRN-119, our ATR inhibitor for the treatment of advanced solid tumors and anticipate initial preliminary data in the fourth quarter 2023,” said Oren Gilad, President and Chief Executive Officer of Aprea.

The company’s Research and Development expenses were $2.2 million for the quarter.

“Our IND enabling studies for ATRN-1051, our WEE1 inhibitor, continue to be on track, and we continue to anticipate filing an IND by the end of the year. Our strong balance sheet continues to support our strategy and plans through our near-term milestones in both our ATR and WEE1 programs, with a cash runway into the fourth quarter of 2024.”

Learn more about the company and their business plans at GlobeNewsWire.

_____